Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › AR › Little Rock › NPI 1790024131
Lab

Physicians Laboratories of America

Physicians Laboratories of America was paid $663K by Medicaid between Feb 2019 and Dec 2024, across 26 billing codes. Its largest line is 80356, — 8.1% of everything it billed.

33Billing provider infoPHYSICIANS LABORATORIES OF AMERICA
LITTLE ROCK, AR 72205
33aNPI1790024131assigned 02/05/2013
28Total paid$663K
24GClaims62,861
24DCodes billed26
24AFirst – last monthFeb 2019 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Arkansas

Rank by total paid#5 of 24
Median peer was paid$53K
This provider vs. median12×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$10K$20K$30K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201914,160$170K
202010,564$103K
202111,007$101K
20226,922$56K
20237,262$86K
2024incomplete12,946$147K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
80356 8.1% 3,487 2,925 $54K
80361 7.5% 3,423 2,895 $50K
80346 6.6% 3,439 2,893 $44K
80348 6.3% 3,374 2,837 $42K
80354 6.0% 3,424 2,882 $40K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 5.9% 1,567 1,372 $39K
80358 5.7% 3,350 2,834 $38K
80365 5.4% 3,350 2,852 $36K
80324 5.3% 3,491 2,924 $35K
80353 4.7% 3,464 2,909 $31K
80372 4.6% 3,392 2,875 $31K
80359 4.3% 3,419 2,877 $28K
14 more codes
80369 4.3% 3,177 $28K
80357 4.1% 3,173 $27K
80373 4.1% 3,336 $27K
80363 3.3% 2,127 $22K
80367 2.5% 2,236 $17K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2.4% 547 $16K
80349 2.3% 1,778 $15K
83992 2.1% 3,372 $14K
80362 1.7% 883 $11K
80368 1.2% 2,132 $8K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.1% 279 $7K
80355 <1% 331 $2K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 220 $632.83
80320 <1% 90 $178.42

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialRICHMOND, JANET (MANAGER)